
AstraZeneca announced that it has commenced dosing patients in a global Phase IIb study to compare the efficacy and safety of AZD9773 (CytoFab) with placebo in adult patients with severe sepsis and/or septic shock receiving best supportive care. Sepsis occurs when the body’s immune system sets off a chain reaction and “overreacts” to an infection. [...]
